Solange Peters, MD, PhD

Articles

Updates from ELCC: 5-Year Update on Pembrolizumab vs Chemotherapy in Advanced NSCLC

May 16th 2023

Jarushka Naidoo, MD, M.B.B.Ch., explains the 5-year-data update from a study investigating single-agent pembrolizumab vs chemotherapy for advanced NSCLC.

Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial

May 16th 2023

The panel reviews data presented at ELCC from EMPOWERLung1 investigating cemiplimab versus chemotherapy in patients with advanced NSCLC.

Data Updates on Single-Agent Immunotherapy in Advanced NSCLC

May 9th 2023

Experts explain recent data updates on single-agent immunotherapy treatment for patient with advanced NSCLC.

Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC

May 9th 2023

Dr Solange Peters reviews data on the efficacy and toxicities of first-line nivolumab and ipilimumab for metastatic non-squamous NSCLC.

Updates in Gender-Based Treatment for Patients with Advanced NSCLC

May 2nd 2023

Jarushka Naidoo, MD, M.B.B.Ch., explains the debate on the gender differences in advanced NSCLC treatment.

CTLA-4 Targeted Regimens in Advanced NSCLC

April 26th 2023

Solange Peters, MD, PhD, detail the subgroups of patients with advanced NSCLC and how treatment varies.

Subgrouping Patients with Advanced NSCLC for Tailored Treatment

April 25th 2023

The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.

Overview of PD-L1 Testing in Advanced NSCLC

April 25th 2023

Marina Garassino, MD, reviews the role of PD-L1 testing in advanced non-small cell lung cancer.

The Exciting Future of NSCLC Treatment

November 23rd 2022

Closing their discussion, the panel shares where they think the NSCLC treatment landscape will be in the future, and what to look forward to.

A Role for Immunotherapy in Patients with Concomitant KRAS and KEAP1/STK11/p53 Mutations

November 16th 2022

The panel explains their approaches to treating patients with mutated NSCLC with immunotherapy.

The ARC-7 Trial of Anti-TGIT Immunotherapies in Advanced NSCLC

November 16th 2022

Dr Johnson reviews data from the ARC-7 trial investigating an anti-PD-L1 plus anti-TGIT combination treatment for advanced NSCLC.

The Role of Anti-TGIT Immunotherapies in the Treatment of Advanced NSCLC

November 9th 2022

Drs Peters and Velcheti provide an overview of the role of anti-TGIT immunotherapies in NSCLC treatment.

Treatment Options in Patients with Advanced NSCLC Who Progress on Immunotherapy

November 9th 2022

Solange Peters, MD, explains the currently available treatment options for patients with advanced NSCLC after progression on immunotherapy.

POSEIDON Study of Dual Immunotherapy Regimens in Advanced NSCLC

November 2nd 2022

Melissa Johnson, MD, explains the design and outcomes of the multi-arm POSEIDON study, which featured a combination of 4 agents for the treatment of advanced NSCLC.

EMPOWER LUNG-3 Study of Chemoimmunotherapy in Advanced NSCLC

November 2nd 2022

Key opinion leaders discuss data from the EMPOWER-Lung-3 study investigating the use of cemiplimab plus chemotherapy in both squamous and non-squamous NSCLC.

KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC

October 26th 2022

Dr Velcheti reviews data on the chemoimmunotherapy treatment of squamous NSCLC from the KEYNOTE-407 study.

CheckMate-227 Study of Frontline Nivolumab and Ipilimumab in Advanced NSCLC

October 26th 2022

Dr Vamsidhar Velcheti explains the 4-year data updates to the CheckMate 227 trial, which investigated PD-L1 monotherapy plus chemotherapy for advanced NSCLC.

Updates in The Treatment of Advanced NSCLC with Immune Checkpoint Inhibitors

October 19th 2022

Drs Peters and Johnson discuss recent updates in the treatment of advanced NSCLC with single- and dual-agent immunotherapy regimens.

Multidisciplinary Therapy and Molecular Testing in Early-Stage NSCLC

October 19th 2022

Dr Melissa Johnson and Dr Myung-Ju Ahn emphasize the importance of a multidisciplinary approach to treatment and biomarker testing for patients with early-stage NSCLC.

Novel HER2-Targeted Therapies for NSCLC

October 17th 2022

Closing out their discussion, the panel highlights investigational therapies in NSCLC to look out for.